CytRx

Orphazyme on last legs amid restructuring, more layoffs

The wheels are almost entirely off Danish biotech Orphazyme after the company’s board of directors called for a court-mediated restructuring.

Max Bayer Mar 10, 2022 6:24pm

NantCell in $356M deal for underperforming CytRx cancer drug

Jul 28, 2017 9:47am

SEC hits out at paid-for bioanalysts, CEOs and firms, charges 27

Apr 11, 2017 8:25am

Weak Phase III sarcoma results see CytRx shares crater

Jul 12, 2016 7:09am